Clinical application of the minimal residual disease monitoring in canine lymphoma

点击翻译按钮获取中文摘要

Overall survival durations after standard chemotherapies have been reported as long as 1 year. In the present study, we assessed the efficacy of the chemotherapeutic protocols objectively by quantification of the minimal residual disease, MRD, after chemotherapy with real-time PCR. Through the results of MRD monitoring, we could propose several strategies to improve the chemotherapeutic protocols such as dose change of the drugs, requirement of the consolidation chemotherapy, and the necessity of the early re-induction chemotherapy during complete remission. The present studies were conceivably very helpful to improve the chemotherapeutic modalities for canine lymphoma as well as indicative of the usefulness of canine lymphoma as an animal model for human non-Hodgkin lymphoma.